本報告已在2011年10月11日停止出版。
更改為出版
Generics: Global Industry Guide
出版日期 : 2011年09月
商品編碼: 217384
Abstract
Datamonitor' s Generics: Global Industry Guide is an essential resource for
top-level data and analysis covering the Generics industry. It includes
detailed data on market size and segmentation, textual analysis of the key
trends and competitive landscape, and profiles of the leading companies. This
incisive report provides expert analysis on a global, regional and country
basis.
Scope of the Report
* Contains an executive summary and data on
value, volume and segmentation
* Provides textual analysis of the
industry' s prospects, competitive landscape and profiles of the leading
companies
* Incorporates in-depth five forces competitive environment analysis and
scorecards
* Covers the Global, European and Asia-Pacific markets as
well as individual chapters on 5 major markets (France, Germany, Japan, the UK
and the US).
* Includes a five-year forecast of the industry
Highlights
The global generics market grew by 5.9% in 2009 to reach a value of $117.7
billion.
In 2014, the global generics market is forecast to have a value of $183.2
billion, an increase of 55.7% since 2009.
Ethical is the largest segment of the global generics market, accounting for
73.4% of the market' s total value.
Asia-Pacific accounts for 36.2% of the global generics market value.
The level of rivalry within the global generics market is reduced somewhat by
strong growth over recent years
Why you should buy this report
* Spot future trends and
developments
* Inform your business decisions
* Add weight
to presentations and marketing materials
* Save time carrying out
entry-level research
Market Definition
The generics market consists of all sales of generic drugs for human use at
ex-manufacturer prices. Datamonitor defines a generic as an
officially-approved copy of an original product whose patent has expired,
marketed either as a brand or using the generic name. This definition excludes
multi-source copy products that make up much of markets such as India, Spain
and Italy. Multi-source copies are drugs still under patent that are offered
by manufacturers other than the patent holders. All currency conversions have
been calculated at constant 2009 average exchange rates
Table of Contents
TABLE OF CONTENTS
EXECUTIVE SUMMARY 2
INTRODUCTION 18
What is this
report about? 18
Who is the target reader? 18
Market definition 18
GLOBAL GENERICS 19
MARKET OVERVIEW 19
MARKET VALUE 20
MARKET
SEGMENTATION I 21
MARKET SEGMENTATION II 22
FIVE FORCES ANALYSIS
23
MARKET FORECASTS 31
GENERICS IN ASIA-PACIFIC 32
MARKET OVERVIEW
32
MARKET VALUE 33
MARKET SEGMENTATION I 34
MARKET SEGMENTATION II
35
FIVE FORCES ANALYSIS 36
MARKET FORECASTS 44
GENERICS IN EUROPE
45
MARKET OVERVIEW 45
MARKET VALUE 46
MARKET SEGMENTATION I 47
MARKET SEGMENTATION II 48
FIVE FORCES ANALYSIS 49
MARKET FORECASTS
57
GENERICS IN BELGIUM 58
MARKET OVERVIEW 58
MARKET VALUE 59
MARKET SEGMENTATION I 60
MARKET SEGMENTATION II 61
FIVE FORCES
ANALYSIS 62
MARKET FORECASTS 70
MACROECONOMIC INDICATORS 71
GENERICS IN CANADA 73
MARKET OVERVIEW 73
MARKET VALUE 74
MARKET
SEGMENTATION I 75
MARKET SEGMENTATION II 76
FIVE FORCES ANALYSIS
77
MARKET FORECASTS 85
MACROECONOMIC INDICATORS 86
GENERICS IN
CHINA 88
MARKET OVERVIEW 88
MARKET VALUE 89
MARKET SEGMENTATION I
90
MARKET SEGMENTATION II 91
FIVE FORCES ANALYSIS 92
MACROECONOMIC
INDICATORS 100
GENERICS IN FRANCE 102
MARKET OVERVIEW 102
MARKET
VALUE 103
MARKET SEGMENTATION I 104
MARKET SEGMENTATION II 105
FIVE FORCES ANALYSIS 106
MARKET FORECASTS 114
MACROECONOMIC INDICATORS
115
GENERICS IN GERMANY 117
MARKET OVERVIEW 117
MARKET VALUE
118
MARKET SEGMENTATION I 119
MARKET SEGMENTATION II 120
FIVE
FORCES ANALYSIS 121
MARKET FORECASTS 129
MACROECONOMIC INDICATORS
130
GENERICS IN ITALY 132
MARKET OVERVIEW 132
MARKET VALUE 133
MARKET SEGMENTATION I 134
MARKET SEGMENTATION II 135
FIVE FORCES
ANALYSIS 136
MARKET FORECASTS 144
MACROECONOMIC INDICATORS 145
GENERICS IN JAPAN 147
MARKET OVERVIEW 147
MARKET VALUE 148
MARKET
SEGMENTATION I 149
MARKET SEGMENTATION II 150
FIVE FORCES ANALYSIS
151
MARKET FORECASTS 159
MACROECONOMIC INDICATORS 160
GENERICS IN
THE NETHERLANDS 162
MARKET OVERVIEW 162
MARKET VALUE 163
MARKET
SEGMENTATION I 164
MARKET SEGMENTATION II 165
FIVE FORCES ANALYSIS
166
MARKET FORECASTS 174
MACROECONOMIC INDICATORS 175
GENERICS IN
SPAIN 177
MARKET OVERVIEW 177
MARKET VALUE 178
MARKET SEGMENTATION
I 179
MARKET SEGMENTATION II 180
FIVE FORCES ANALYSIS 181
MARKET
FORECASTS 189
MACROECONOMIC INDICATORS 190
GENERICS IN THE UNITED
KINGDOM 192
MARKET OVERVIEW 192
MARKET VALUE 193
MARKET
SEGMENTATION I 194
MARKET SEGMENTATION II 195
FIVE FORCES ANALYSIS
196
MARKET FORECASTS 204
MACROECONOMIC INDICATORS 205
GENERICS IN
THE UNITED STATES 207
MARKET OVERVIEW 207
MARKET VALUE 208
MARKET
SEGMENTATION I 209
MARKET SEGMENTATION II 210
FIVE FORCES ANALYSIS
211
MARKET FORECASTS 219
MACROECONOMIC INDICATORS 220
COMPANY
PROFILES 222
LEADING COMPANIES 222
APPENDIX 241
Data Research
Methodology 241
About Datamonitor 242
Disclaimer 242
LIST OF
TABLES
Table 1: Global generics market value: $ billion, 2005-09
21
Table 2: Global generics market segmentation I:% share, by value, 2009
22
Table 3: Global generics market segmentation II: % share, by value,
2009 23
Table 4: Global generics market value forecast: $ billion,
2009-14 32
Table 5: Asia-Pacific generics market value: $ billion,
2005-09 34
Table 6: Asia-Pacific generics market segmentation I:%
share, by value, 2009 35
Table 7: Asia-Pacific generics market
segmentation II: % share, by value, 2009 36
Table 8: Asia-Pacific generics
market value forecast: $ billion, 2009-14 45
Table 9: Europe
generics market value: $ billion, 2005-09 47
Table 10: Europe
generics market segmentation I:% share, by value, 2009 48
Table 11: Europe
generics market segmentation II: % share, by value, 2009 49
Table 12:
Europe generics market value forecast: $ billion, 2009-14 58
Table
13: Belgium generics market value: $ million, 2005-09 60
Table 14:
Belgium generics market segmentation I:% share, by value, 2009 61
Table
15: Belgium generics market segmentation II: % share, by value, 2009 62
Table 16: Belgium generics market value forecast: $ million, 2009-14
71
Table 17: Belgium size of population (million), 2005-09 72
Table 18: Belgium gdp (constant 2000 prices, $ billion), 2005-09 72
Table 19: Belgium gdp (current prices, $ billion), 2005-09 72
Table
20: Belgium inflation, 2005-09 73
Table 21: Belgium consumer price
index (absolute), 2005-09 73
Table 22: Belgium exchange rate,
2005-09 73
Table 23: Canada generics market value: $ billion,
2005-09 75
Table 24: Canada generics market segmentation I:% share,
by value, 2009 76
Table 25: Canada generics market segmentation II: %
share, by value, 2009 77
Table 26: Canada generics market value forecast:
$ billion, 2009-14 86
Table 27: Canada size of population (million),
2005-09 87
Table 28: Canada gdp (constant 2000 prices, $ billion),
2005-09 87
Table 29: Canada gdp (current prices, $ billion),
2005-09 87
Table 30: Canada inflation, 2005-09 88
Table
31: Canada consumer price index (absolute), 2005-09 88
Table 32:
Canada exchange rate, 2005-09 88
Table 33: China generics market
value: $ billion, 2005-09 90
Table 34: China generics market
segmentation I:% share, by value, 2009 91
Table 35: China generics market
segmentation II: % share, by value, 2009 92
Table 36: China size of
population (million), 2005-09 101
Table 37: China gdp (constant 2000
prices, $ billion), 2005-09 101
Table 38: China gdp (current prices,
$ billion), 2005-09 101
Table 39: China inflation, 2005-09
102
Table 40: China consumer price index (absolute), 2005-09 102
Table 41: China exchange rate, 2005-09 102
Table 42: France generics
market value: $ billion, 2005-09 104
Table 43: France generics
market segmentation I:% share, by value, 2009 105
Table 44: France
generics market segmentation II: % share, by value, 2009 106
Table 45:
France generics market value forecast: $ billion, 2009-14 115
Table
46: France size of population (million), 2005-09 116
Table 47:
France gdp (constant 2000 prices, $ billion), 2005-09 116
Table 48:
France gdp (current prices, $ billion), 2005-09 116
Table 49: France
inflation, 2005-09 117
Table 50: France consumer price index
(absolute), 2005-09 117
Table 51: France exchange rate,
2005-09 117
Table 52: Germany generics market value: $ billion,
2005-09 119
Table 53: Germany generics market segmentation I:%
share, by value, 2009 120
Table 54: Germany generics market segmentation
II: % share, by value, 2009 121
Table 55: Germany generics market value
forecast: $ billion, 2009-14 130
Table 56: Germany size of
population (million), 2005-09 131
Table 57: Germany gdp (constant
2000 prices, $ billion), 2005-09 131
Table 58: Germany gdp (current
prices, $ billion), 2005-09 131
Table 59: Germany inflation,
2005-09 132
Table 60: Germany consumer price index (absolute),
2005-09 132
Table 61: Germany exchange rate, 2005-09 132
Table 62: Italy generics market value: $ million, 2005-09 134
Table
63: Italy generics market segmentation I:% share, by value, 2009 135
Table
64: Italy generics market segmentation II: % share, by value, 2009 136
Table 65: Italy generics market value forecast: $ million, 2009-14
145
Table 66: Italy size of population (million), 2005-09 146
Table 67: Italy gdp (constant 2000 prices, $ billion), 2005-09 146
Table 68: Italy gdp (current prices, $ billion), 2005-09 146
Table
69: Italy inflation, 2005-09 147
Table 70: Italy consumer price
index (absolute), 2005-09 147
Table 71: Italy exchange rate,
2005-09 147
Table 72: Japan generics market value: $ billion,
2005-09 149
Table 73: Japan generics market segmentation I:% share,
by value, 2009 150
Table 74: Japan generics market segmentation II: %
share, by value, 2009 151
Table 75: Japan generics market value forecast:
$ billion, 2009-14 160
Table 76: Japan size of population (million),
2005-09 161
Table 77: Japan gdp (constant 2000 prices, $ billion),
2005-09 161
Table 78: Japan gdp (current prices, $ billion),
2005-09 161
Table 79: Japan inflation, 2005-09 162
Table
80: Japan consumer price index (absolute), 2005-09 162
Table 81:
Japan exchange rate, 2005-09 162
Table 82: Netherlands generics
market value: $ million, 2005-09 164
Table 83: Netherlands generics
market segmentation I:% share, by value, 2009 165
Table 84: Netherlands
generics market segmentation II: % share, by value, 2009 166
Table 85:
Netherlands generics market value forecast: $ million, 2009-14 175
Table 86: Netherlands size of population (million), 2005-09 176
Table 87: Netherlands gdp (constant 2000 prices, $ billion), 2005-09
176
Table 88: Netherlands gdp (current prices, $ billion), 2005-09
176
Table 89: Netherlands inflation, 2005-09 177
Table 90:
Netherlands consumer price index (absolute), 2005-09 177
Table 91:
Netherlands exchange rate, 2005-09 177
Table 92: Spain generics
market value: $ billion, 2005-09 179
Table 93: Spain generics market
segmentation I:% share, by value, 2009 180
Table 94: Spain generics market
segmentation II: % share, by value, 2009 181
Table 95: Spain generics
market value forecast: $ billion, 2009-14 190
Table 96: Spain size
of population (million), 2005-09 191
Table 97: Spain gdp (constant
2000 prices, $ billion), 2005-09 191
Table 98: Spain gdp (current
prices, $ billion), 2005-09 191
Table 99: Spain inflation,
2005-09 192
Table 100: Spain consumer price index (absolute),
2005-09 192
Table 101: Spain exchange rate, 2005-09 192
Table 102: United Kingdom generics market value: $ billion, 2005-09
194
Table 103: United Kingdom generics market segmentation I:% share, by
value, 2009 195
Table 104: United Kingdom generics market segmentation II:
% share, by value, 2009 196
Table 105: United Kingdom generics market
value forecast: $ billion, 2009-14 205
Table 106: United Kingdom
size of population (million), 2005-09 206
Table 107: United Kingdom
gdp (constant 2000 prices, $ billion), 2005-09 206
Table 108: United
Kingdom gdp (current prices, $ billion), 2005-09 206
Table 109:
United Kingdom inflation, 2005-09 207
Table 110: United Kingdom
consumer price index (absolute), 2005-09 207
Table 111: United
Kingdom exchange rate, 2005-09 207
Table 112: United States generics
market value: $ billion, 2005-09 209
Table 113: United States
generics market segmentation I:% share, by value, 2009 210
Table 114:
United States generics market segmentation II: % share, by value, 2009 211
Table 115: United States generics market value forecast: $ billion,
2009-14 220
Table 116: United States size of population (million),
2005-09 221
Table 117: United States gdp (constant 2000 prices, $
billion), 2005-09 221
Table 118: United States gdp (current prices,
$ billion), 2005-09 221
Table 119: United States inflation,
2005-09 222
Table 120: United States consumer price index
(absolute), 2005-09 222
Table 121: United States exchange rate,
2005-09 222
Table 122: Bayer AG: key facts 223
Table 123: Bayer
AG: key financials ($) 226
Table 124: Bayer AG: key financials (€)
226
Table 125: Bayer AG: key financial ratios 227
Table 126: Mylan
Laboratories Inc.: key facts 229
Table 127: Mylan Laboratories Inc.: key
financials ($) 230
Table 128: Mylan Laboratories Inc.: key financial
ratios 230
Table 129: Novartis AG: key facts 233
Table 130: Novartis
AG: key financials ($) 234
Table 131: Novartis AG: key financial ratios
235
Table 132: Teva Pharmaceutical Industries: key facts 237
Table
133: Teva Pharmaceutical Industries: key financials ($) 239
Table 134:
Teva Pharmaceutical Industries: key financial ratios 240
LIST OF
FIGURES
Figure 1: Global generics market value: $ billion, 2005-09
21
Figure 2: Global generics market segmentation I:% share, by value, 2009
22
Figure 3: Global generics market segmentation II: % share, by value,
2009 23
Figure 4: Forces driving competition in the global generics
market, 2009 24
Figure 5: Drivers of buyer power in the global generics
market, 2009 26
Figure 6: Drivers of supplier power in the global generics
market, 2009 27
Figure 7: Factors influencing the likelihood of new
entrants in the global generics market, 2009 28
Figure 8: Factors
influencing the threat of substitutes in the global generics market, 2009
30
Figure 9: Drivers of degree of rivalry in the global generics market,
2009 31
Figure 10: Global generics market value forecast: $ billion,
2009-14 32
Figure 11: Asia-Pacific generics market value: $ billion,
2005-09 34
Figure 12: Asia-Pacific generics market segmentation I:%
share, by value, 2009 35
Figure 13: Asia-Pacific generics market
segmentation II: % share, by value, 2009 36
Figure 14: Forces driving
competition in the generics market in Asia-Pacific, 2009 37
Figure 15:
Drivers of buyer power in the generics market in Asia-Pacific, 2009 39
Figure 16: Drivers of supplier power in the generics market in Asia-Pacific,
2009 40
Figure 17: Factors influencing the likelihood of new entrants in
the generics market in Asia-Pacific, 2009 41
Figure 18: Factors
influencing the threat of substitutes in the generics market in Asia-Pacific,
2009 43
Figure 19: Drivers of degree of rivalry in the generics market in
Asia-Pacific, 2009 44
Figure 20: Asia-Pacific generics market value
forecast: $ billion, 2009-14 45
Figure 21: Europe generics market
value: $ billion, 2005-09 47
Figure 22: Europe generics market
segmentation I:% share, by value, 2009 48
Figure 23: Europe generics
market segmentation II: % share, by value, 2009 49
Figure 24: Forces
driving competition in the generics market in Europe, 2009 50
Figure 25:
Drivers of buyer power in the generics market in Europe, 2009 52
Figure
26: Drivers of supplier power in the generics market in Europe, 2009 53
Figure 27: Factors influencing the likelihood of new entrants in the generics
market in Europe, 2009 54
Figure 28: Factors influencing the threat of
substitutes in the generics market in Europe, 2009 56
Figure 29: Drivers
of degree of rivalry in the generics market in Europe, 2009 57
Figure 30:
Europe generics market value forecast: $ billion, 2009-14 58
Figure
31: Belgium generics market value: $ million, 2005-09 60
Figure 32:
Belgium generics market segmentation I:% share, by value, 2009 61
Figure
33: Belgium generics market segmentation II: % share, by value, 2009 62
Figure 34: Forces driving competition in the generics market in Belgium, 2009
63
Figure 35: Drivers of buyer power in the generics market in Belgium,
2009 65
Figure 36: Drivers of supplier power in the generics market in
Belgium, 2009 66
Figure 37: Factors influencing the likelihood of new
entrants in the generics market in Belgium, 2009 67
Figure 38: Factors
influencing the threat of substitutes in the generics market in Belgium, 2009
69
Figure 39: Drivers of degree of rivalry in the generics market in
Belgium, 2009 70
Figure 40: Belgium generics market value forecast: $
million, 2009-14 71
Figure 41: Canada generics market value: $
billion, 2005-09 75
Figure 42: Canada generics market segmentation
I:% share, by value, 2009 76
Figure 43: Canada generics market
segmentation II: % share, by value, 2009 77
Figure 44: Forces driving
competition in the generics market in Canada, 2009 78
Figure 45: Drivers
of buyer power in the generics market in Canada, 2009 80
Figure 46:
Drivers of supplier power in the generics market in Canada, 2009 81
Figure
47: Factors influencing the likelihood of new entrants in the generics market
in Canada, 2009 82
Figure 48: Factors influencing the threat of
substitutes in the generics market in Canada, 2009 84
Figure 49: Drivers
of degree of rivalry in the generics market in Canada, 2009 85
Figure 50:
Canada generics market value forecast: $ billion, 2009-14 86
Figure
51: China generics market value: $ billion, 2005-09 90
Figure 52:
China generics market segmentation I:% share, by value, 2009 91
Figure 53:
China generics market segmentation II: % share, by value, 2009 92
Figure
54: Forces driving competition in the generics market in China, 2009 93
Figure 55: Drivers of buyer power in the generics market in China, 2009 95
Figure 56: Drivers of supplier power in the generics market in China, 2009
96
Figure 57: Factors influencing the likelihood of new entrants in the
generics market in China, 2009 97
Figure 58: Factors influencing the
threat of substitutes in the generics market in China, 2009 99
Figure 59:
Drivers of degree of rivalry in the generics market in China, 2009 100
Figure 60: France generics market value: $ billion, 2005-09 104
Figure 61: France generics market segmentation I:% share, by value, 2009
105
Figure 62: France generics market segmentation II: % share, by value,
2009 106
Figure 63: Forces driving competition in the generics market in
France, 2009 107
Figure 64: Drivers of buyer power in the generics market
in France, 2009 109
Figure 65: Drivers of supplier power in the generics
market in France, 2009 110
Figure 66: Factors influencing the likelihood
of new entrants in the generics market in France, 2009 111
Figure 67:
Factors influencing the threat of substitutes in the generics market in
France, 2009 113
Figure 68: Drivers of degree of rivalry in the generics
market in France, 2009 114
Figure 69: France generics market value
forecast: $ billion, 2009-14 115
Figure 70: Germany generics market
value: $ billion, 2005-09 119
Figure 71: Germany generics market
segmentation I:% share, by value, 2009 120
Figure 72: Germany generics
market segmentation II: % share, by value, 2009 121
Figure 73: Forces
driving competition in the generics market in Germany, 2009 122
Figure 74:
Drivers of buyer power in the generics market in Germany, 2009 124
Figure
75: Drivers of supplier power in the generics market in Germany, 2009 125
Figure 76: Factors influencing the likelihood of new entrants in the generics
market in Germany, 2009 126
Figure 77: Factors influencing the threat of
substitutes in the generics market in Germany, 2009 128
Figure 78: Drivers
of degree of rivalry in the generics market in Germany, 2009 129
Figure
79: Germany generics market value forecast: $ billion, 2009-14 130
Figure 80: Italy generics market value: $ million, 2005-09 134
Figure 81: Italy generics market segmentation I:% share, by value, 2009
135
Figure 82: Italy generics market segmentation II: % share, by value,
2009 136
Figure 83: Forces driving competition in the generics market in
Italy, 2009 137
Figure 84: Drivers of buyer power in the generics market
in Italy, 2009 139
Figure 85: Drivers of supplier power in the generics
market in Italy, 2009 140
Figure 86: Factors influencing the likelihood of
new entrants in the generics market in Italy, 2009 141
Figure 87: Factors
influencing the threat of substitutes in the generics market in Italy, 2009
143
Figure 88: Drivers of degree of rivalry in the generics market in
Italy, 2009 144
Figure 89: Italy generics market value forecast: $
million, 2009-14 145
Figure 90: Japan generics market value: $
billion, 2005-09 149
Figure 91: Japan generics market segmentation
I:% share, by value, 2009 150
Figure 92: Japan generics market
segmentation II: % share, by value, 2009 151
Figure 93: Forces driving
competition in the generics market in Japan, 2009 152
Figure 94: Drivers
of buyer power in the generics market in Japan, 2009 154
Figure 95:
Drivers of supplier power in the generics market in Japan, 2009 155
Figure
96: Factors influencing the likelihood of new entrants in the generics market
in Japan, 2009 156
Figure 97: Factors influencing the threat of
substitutes in the generics market in Japan, 2009 158
Figure 98: Drivers
of degree of rivalry in the generics market in Japan, 2009 159
Figure 99:
Japan generics market value forecast: $ billion, 2009-14 160
Figure
100: Netherlands generics market value: $ million, 2005-09 164
Figure 101: Netherlands generics market segmentation I:% share, by value, 2009
165
Figure 102: Netherlands generics market segmentation II: % share, by
value, 2009 166
Figure 103: Forces driving competition in the generics
market in the Netherlands, 2009 167
Figure 104: Drivers of buyer power in
the generics market in the Netherlands, 2009 169
Figure 105: Drivers of
supplier power in the generics market in the Netherlands, 2009 170
Figure
106: Factors influencing the likelihood of new entrants in the generics market
in the Netherlands, 2009 171
Figure 107: Factors influencing the threat of
substitutes in the generics market in the Netherlands, 2009 173
Figure
108: Drivers of degree of rivalry in the generics market in the Netherlands,
2009 174
Figure 109: Netherlands generics market value forecast: $
million, 2009-14 175
Figure 110: Spain generics market value: $
billion, 2005-09 179
Figure 111: Spain generics market segmentation
I:% share, by value, 2009 180
Figure 112: Spain generics market
segmentation II: % share, by value, 2009 181
Figure 113: Forces driving
competition in the generics market in Spain, 2009 182
Figure 114: Drivers
of buyer power in the generics market in Spain, 2009 184
Figure 115:
Drivers of supplier power in the generics market in Spain, 2009 185
Figure
116: Factors influencing the likelihood of new entrants in the generics market
in Spain, 2009 186
Figure 117: Factors influencing the threat of
substitutes in the generics market in Spain, 2009 188
Figure 118: Drivers
of degree of rivalry in the generics market in Spain, 2009 189
Figure 119:
Spain generics market value forecast: $ billion, 2009-14 190
Figure
120: United Kingdom generics market value: $ billion, 2005-09 194
Figure 121: United Kingdom generics market segmentation I:% share, by value,
2009 195
Figure 122: United Kingdom generics market segmentation II: %
share, by value, 2009 196
Figure 123: Forces driving competition in the
generics market in the United Kingdom, 2009 197
Figure 124: Drivers of
buyer power in the generics market in the United Kingdom, 2009 199
Figure
125: Drivers of supplier power in the generics market in the United Kingdom,
2009 200
Figure 126: Factors influencing the likelihood of new entrants in
the generics market in the United Kingdom, 2009 201
Figure 127: Factors
influencing the threat of substitutes in the generics market in the United
Kingdom, 2009 203
Figure 128: Drivers of degree of rivalry in the generics
market in the United Kingdom, 2009 204
Figure 129: United Kingdom generics
market value forecast: $ billion, 2009-14 205
Figure 130: United
States generics market value: $ billion, 2005-09 209
Figure 131:
United States generics market segmentation I:% share, by value, 2009 210
Figure 132: United States generics market segmentation II: % share, by value,
2009 211
Figure 133: Forces driving competition in the generics market in
the United States, 2009 212
Figure 134: Drivers of buyer power in the
generics market in the United States, 2009 214
Figure 135: Drivers of
supplier power in the generics market in the United States, 2009 215
Figure 136: Factors influencing the likelihood of new entrants in the generics
market in the United States, 2009 216
Figure 137: Factors influencing the
threat of substitutes in the generics market in the United States, 2009
218
Figure 138: Drivers of degree of rivalry in the generics market in the
United States, 2009 219
Figure 139: United States generics market value
forecast: $ billion, 2009-14 220
Figure 140: Bayer AG: revenues &
profitability 227
Figure 141: Bayer AG: assets & liabilities 228
Figure 142: Mylan Laboratories Inc.: revenues & profitability 231
Figure
143: Mylan Laboratories Inc.: assets & liabilities 232
Figure 144:
Novartis AG: revenues & profitability 235
Figure 145: Novartis AG: assets
& liabilities 236
Figure 146: Teva Pharmaceutical Industries: revenues &
profitability 240
Figure 147: Teva Pharmaceutical Industries: assets &
liabilities 241
